Do you have COPD and repeated breathing flares ending up in the hospital? If you are under the care of a doctor at UNC, you may be eligible for a research study to find out which of two medicines, roflumilast or azithromycin, can help your COPD control.

Researchers are looking for current and former smokers with or without COPD to enroll in a registry to be contacted for future studies.

To collect research samples from CF patients already having a clinically indicated colonoscopy. We're collecting a few additional samples on top of what is collected for clinical purposes to give to researchers for future projects. This will increase your time of procedure around 5 minutes.

There is a movement toward addressing social risk factors as part of healthcare delivery, with similar efforts launched by the CF Foundation. However, current social screening tools do not capture the unique risks and needs of people with CF, have not been tailored to adults with CF vs caregivers of children with CF, and have not been adapted to multidisciplinary CF care delivery. Our work also showed <20% of those who report needs access help, and found barriers related to stigma, guilt, or fear. It is critical to develop a social screening instrument that is specific to adults and caregivers of children with CF, acceptable to them, and rigorously tested for reliability and validity. Using a community-engaged process, we will systematically address these knowledge gaps.

Primary: To demonstrate the safety of autologous LSCs administered by intravenous infusion in patients with idiopathic pulmonary fibrosis. Secondary: To demonstrate the efficacy of autologous LSCs administered by intravenous infusion in patients with idiopathic pulmonary fibrosis.

Evaluate the regional lung function and structural changes using MRI in children with cystic fibrosis (CF) prescribed either immediate or tailored therapy for their pulmonary exacerbation. The primary outcome measure for this ancillary study is the change in ventilation defect percentage (VDP) calculated from Xe MRI, which represents the fraction of the lung with absent or reduced ventilation.

This is a 24-week Phase 2, double-blind study testing the safety of PF-07868489 in patients with Pulmonary Arterial Hypertension (PAH). The primary objective is to evaluate PF-07868489 vs placebo in patients with PAH. The study will evaluate the occurrence of adverse events, change in baseline vital signs and laboratory values, as well as changes in baseline electrocardiogram (ECG) characteristics

Evaluate the differences between two different treatment durations for exacerbations in a pediatric sample to determine which should be clinical standard.

We are performing a clinical study to determine the optimal frequency for medications for infected pleural fluid, referred to as intrapleural enzyme therapy (IET). Participants will either receive once daily IET or twice daily IET. We hypothesize that once daily IET will be non-inferior to twice daily IET.

We are looking for links between cystic fibrosis outcomes and a history of intimate partner violence.